We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Adverse Event Brings Solid Biosciences DMD Gene Therapy Trial to Halt
Adverse Event Brings Solid Biosciences DMD Gene Therapy Trial to Halt
Another Duchenne muscular dystrophy gene therapy trial has been held up by the FDA following a serious adverse event in one patient. The agency halted Solid Biosciences’ trial of SGT-001 twice before due to reported serious adverse events.